SEC Comment Letter 0000000000-23-002325 to Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972) (CGEM)
Cullinan Therapeutics, Inc. (CGEM) (CIK 0001789972)
Date: March 9, 2023 · CIK: 0001789972 · Accession: 0000000000-23-002325
AI Filing Summary & Sentiment
File numbers found in text: 333-270384
Letter
United States securities and exchange commission logo March 9, 2023 Jeff Trigilio Chief Financial Officer Cullinan Oncology, Inc. One Main Street, Suite 1350 Cambridge, MA 02142 Re:Cullinan Oncology, Inc. Registration Statement on Form S-3 Filed March 9, 2023 File No. 333-270384 Dear Jeff Trigilio: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas J. Danielski
Show Raw Text
United States securities and exchange commission logo
March 9, 2023
Jeff Trigilio
Chief Financial Officer
Cullinan Oncology, Inc.
One Main Street, Suite 1350
Cambridge, MA 02142
Re:Cullinan Oncology, Inc.
Registration Statement on Form S-3
Filed March 9, 2023
File No. 333-270384
Dear Jeff Trigilio:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Thomas J. Danielski